An Overview of MET Exon 14 Mutation Testing and Treatment in Advanced NSCLC
  • CME

Gain expert insight on the optimal testing methods for and latest therapies targeting MET exon 14 skipping mutations in NSCLC by watching this on-demand Webcast of a live CCO Webinar.  
D. Ross Camidge, MD, PhD
Luis Paz-Ares, MD, PhD
Karen L. Reckamp, MD, MS
Physicians: maximum of 1.25 AMA PRA Category 1 Credits
Released: July 24, 2020 Expiration: July 23, 2021
Multimedia An Overview of MET Exon 14 Mutation Testing and Treatment in Advanced NSCLC
This program is divided into short segments that you can review from the Activity landing page.
MET Alterations: Mastering the Features of and Testing for a New Target in NSCLC (35 mins)
Watch this expert overview of MET gene alterations in NSCLC, including guidance on testing for targetable METex14-skipping mutations.
Launch MET Alterations: Mastering the Features of and Testing for a New Target in NSCLC (35 mins)
New Selective MET-Targeted Therapies for METex14-Positive NSCLC (26 mins)
Get up to date on the latest clinical data for MET-targeted therapies and gain expert insight on their optimal use in the treatment of METex14-positive NSCLC.
Launch New Selective MET-Targeted Therapies for METex14-Positive NSCLC (26 mins)
MET and Acquired Resistance in Advanced NSCLC (22 mins)
Gain expert insight into the role of MET amplification in TKI pretreated EGFR- and ALK-altered NSCLC and acquired resistance to MET TKIs in MET-altered NSCLC, including next-line treatment choices. 
Launch MET and Acquired Resistance in Advanced NSCLC (22 mins)

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Describe the rationale for METex14 as a targetable alteration in NSCLC
  • Evaluate the available testing platforms and use of tissue and plasma biopsies to assess METex14 in patients with NSCLC
  • Discuss the available clinical evidence for selective MET inhibitors in METex14-altered NSCLC, including an assessment of relative efficacy and central nervous system responses
  • Appropriately manage treatment-related adverse events associated with MET targeted agents used in patients with advanced-stage NSCLC

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

This educational activity is supported by an independent grant from the Healthcare business of
Merck KGaA

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty

D. Ross Camidge, MD, PhD

Professor of Medicine/Oncology
University of Colorado Cancer Center
Aurora, Colorado

D. Ross Camidge, MD, PhD, has disclosed that he has received consulting fees from 14ner Oncology, AbbVie, Achilles, Apollomics, Archer, BeyondSpring, Biothera, Blueprint, Bristol-Myers Squibb, CBT Pharmaceuticals, Daiichi Sankyo, EMD Serono, G1 Therapeutics, Helssin, Lilly, Medtronic, Ribon, and Takeda and funds for research support paid to his institution from AbbVie, AstraZeneca, Bristol-Myers Squibb, Hansoh, Lycera, Medimmune, Merck, Pfizer, Phosplatin, Roche/Genentech, Seattle Genetics, Symphogen, and Takeda.
Luis Paz-Ares, MD, PhD

Medical Oncology
University Hospital Doce de Octubre
Madrid, Spain

Luis Paz-Ares, MD, PhD, has disclosed that he has received honoraria from AstraZeneca, Bristol-Myers Squibb, Lilly, MSD, Novartis, Pfizer, and Roche.
Karen L. Reckamp, MD, MS

Professor of Medicine
Director
, Division of Medical Oncology
Department of Medicine
Cedars Sinai
Los Angeles, California

Karen L. Reckamp, MD, MS, has disclosed that she has received consulting fees from AstraZeneca, Boehringer Ingelheim, Calithera, Genentech, Guardant, Precision Health, and Tesaro and funds for research support paid to her prior institution from AbbVie, Acea, Adaptimmune, Boehringer Ingelheim, Bristol-Myers Squibb, Genentech, GlaxoSmithKline, Guardant, Janssen, Loxo Oncology, Molecular Partners, Seattle Genetics, Spectrum, Takeda, Xcovery, and Zeno.

Staff

Rachael M. Andrie, PhD

Scientific Director

Rachael M. Andrie, PhD, has no relevant conflicts of interest to report.
Marie N. Becker, PhD

Scientific Director

Marie N. Becker, PhD, has no relevant conflicts of interest to report.
Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant conflicts of interest to report.
Gordon Kelley

Senior Clinical Editor

Gordon Kelley has no relevant conflicts of interest to report.
Petra Cravens, PhD

Editorial Contributor

Petra Cravens, PhD, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Katie Eustace, MBA

Senior Director, Global Medical Education, Europe

Katie Eustace, MBA, has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

The goal of this activity is to improve the knowledge and competence of learners to apply practice-changing clinical data and expert recommendations to optimize the care of their patients with MET-altered NSCLC.

Goal

This program is intended for global medical oncologists, pulmonologists, and other healthcare providers who care for patients with NSCLC.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from July 24, 2020, through July 23, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Gain key clinical insights fast with this short slideset from CCO on RET fusion–positive NSCLC

Dara L. Aisner, MD, PhD Joshua Bauml, MD Released: September 17, 2020

Gain key expert insights fast with this short slideset from CCO on biomarkers critical to optimal use of targeted therapy and immunotherapy for NSCLC

Matthew Gubens, MD, MS Sanjay Mukhopadhyay, MD Released: September 11, 2020

Downloadable slideset on established and emerging biomarkers critical to optimal use of targeted therapy and immunotherapy in NSCLC, from Clinical Care Options (CCO)

Matthew Gubens, MD, MS Released: September 11, 2020

Downloadable slideset on best practices when biopsying and testing for NSCLC biomarkers, from Clinical Care Options (CCO)

Sanjay Mukhopadhyay, MD Released: September 11, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?